USPTO serial 79412060
ZYMEWORKS
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- LARKEY, MICHAEL M
- Law office
- TMO LAW OFFICE 116
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with ZYMEWORKS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kiranjit K Dharsan
Kiranjit K Dharsan Seiter IP1110 N Virgil Ave, Suite #98436Los Angeles, CA 90029United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; medicines for human purposes for the treatment of cancer, autoimmune and autoinflammatory diseases; diagnostic preparations for medical purposes; chemical preparations for pharmaceutical and medical purposes, namely, the treatment and diagnosis of cancer, autoimmune and autoinflammatory diseases; chemical preparations for pharmaceutical and medical purposes, namely, regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; biological preparations for medical and pharmaceutical purposes, namely, biologic and recombinant therapeutic agents comprised of monoclonal antibodies, multispecific and bispecific antibodies, antibody fragments, antibody-drug conjugates, fusion proteins, recombinant proteins, cytokines, peptides, and nucleic acid-based biologics and their constituents, derivatives, variants, conjugates, and formulations; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of cancer; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human autoimmune diseases, disorders and conditions; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human inflammatory diseases, disorders and conditions | ACTIVE | — |
| 042 | Chemical, biochemical and biological research and analysis; research and development in the field of biotechnology; medical and pharmacological research services and product development in the field of biologics, proteomics, and antibody engineering; pharmaceutical products development and pharmaceutical product evaluation; scientific research in the nature of conducting clinical trials for others for pharmaceutical products; scientific research and development of preparations, agents and technology for the development of antibody therapeutics for the treatment, and prophylaxis of human diseases, disorders and conditions, namely, cancer, auto immune and inflammatory diseases; providing scientific information to scientists, physicians and health care providers in the fields of cancer, auto immune diseases, inflammatory diseases, and infectious diseases; chemical molecular analysis provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms; product optimization services, namely, research and development services of new pharmaceutical products provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms | ACTIVE | — |
| 045 | Intellectual property licensing services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 28, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 28, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 28, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 28, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 21, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 3, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 3, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 1, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 31, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |